ME00519B - Antitijela visokog afiniteta prema humanom il-6 receptoru - Google Patents
Antitijela visokog afiniteta prema humanom il-6 receptoruInfo
- Publication number
- ME00519B ME00519B MEP-2008-853A MEP85308A ME00519B ME 00519 B ME00519 B ME 00519B ME P85308 A MEP85308 A ME P85308A ME 00519 B ME00519 B ME 00519B
- Authority
- ME
- Montenegro
- Prior art keywords
- seq
- antibody
- binding fragment
- antigen
- heavy chain
- Prior art date
Links
- 102000010781 Interleukin-6 Receptors Human genes 0.000 title 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 claims abstract 20
- 239000000427 antigen Substances 0.000 claims abstract 17
- 102000036639 antigens Human genes 0.000 claims abstract 17
- 108091007433 antigens Proteins 0.000 claims abstract 17
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims abstract 2
- 102000052611 human IL6 Human genes 0.000 claims abstract 2
- 102000005962 receptors Human genes 0.000 claims abstract 2
- 108020003175 receptors Proteins 0.000 claims abstract 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 102000004889 Interleukin-6 Human genes 0.000 claims 4
- 108090001005 Interleukin-6 Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 241000282412 Homo Species 0.000 claims 3
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 102000052623 human IL6R Human genes 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 241000588724 Escherichia coli Species 0.000 claims 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Claims (19)
1. Antitelo ili njegov antigen-vezujući fragment, koji se specifično vezuje za humani interleukin-6 receptor (hIL-6R) sa KD od otprilike 500 pM i manjom i, 300 pM i manjom, mereno površinskom plazmon rezonancom.
2. Antitelo ili njegov antigen-vezujući fragment, kao u patentnom zahtevu 1, koje vezuje hIL-6R sa afinitetom od najmanje 2-puta većim u odnosu na njegovo vezivanje za majmunski IL-6R.
3. Antitelo ili antigen vezujući fragment, kao u patentnom zahtevu 1 ili 2, koji sadrže domen komplementarnog determinišućeg regiona 3 (CDR3)teškog lanca i CDR3 domen lakog lanca, gde: teški lanac CDR3 domena obuhvata amino kiselinsku sekvencu formule: X1-X2-X3-X4-X1-X2-X1-X8-X9-X10-X11-X12-X13-X14-X15-X16-X11-X18-X19 (SEQ ID NO: 247) u kojoj je: X1=Ala, X2=Lys, X3=Gly, X4=Arg, X1=Asp, X2=Ser ili Ala, X7=Phe, X8=Asp, X9=Ile, X10=Pro ili ga nema, X11=Phe ili ga nema, X12=Val ili ga nema, X13=Tyr ili ga nema, Xl4=Tyr ili ga nema, X15=Tyr ili ga nema, Xl6=Gly ili ga nema, X17 =Met ili ga nema, X18=Asp ili ga nema i, X19=Val ili ga nema; i laki lanac CDR3 domena obuhvata amino kiselinsku sekvencu formule: X1-X2-X3-X4-X1-X2-X7-X8-X9(SEQ ID NO: 250) u kojoj je: X1=Gln, X2=Gln ili His, X3=Ala, X4=Asn ili Tyr, X1=Ser, X2=Phe, X7=Pro, X2=Pro i, X9=Thr.
4. Antitelo ili antigen vezujući fragment, kao u patentnom zahtevu 3, koji dalje sadrže teški lanac CDR1 domena, koji obuhvata amino kiselinsku sekvencu formule: X1-X2-X3-X4-X5-X6-X7-X8 (SEQ ID NO: 245) u kojoj je: X1=Gly ili Arg, X2=Phe, X3=Thr, X4=Phe, X1=Asp, X2=Asp, X7=Tyr i, X8=Ala; teški lanac CDR2 domena, koji obuhvata amino kiselinsku sekvencu formule: X1-X2-X3-X4-X1-X2-X7-X8 (SEQ ID NO: 246) u kojoj je: X1=Ile ili Val, X2=Ser, X3=Trp, X4=Asn, X1=Ser, X2=Gly, X7=Ser i, X8=Ile; laki lanac CDR1 domena, koji obuhvata amino kiselinsku sekvencu formule: X1-X2-X3-X4-X5-X6-X7-X8 (SEQ ID NO: 248) u kojoj je: X1=Gln, X2=Gly, X3=Ile, X4=Ser, X1=Ser i, X6=Trp; i laki lanac CDR2 domena, koji obuhvata amino kiselinsku sekvencu formule: X3-X2-X3 (SEQ ID NO: 249) u kojoj je: X1=Gly ili Ala, X2=Ala i, X3=Ser.
5. Antitelo ili antigen vezujući fragment, kao u patentnom zahtevu 1 ili 2, koji sadrže: teški lanac CDR3 domena koji je odabran iz grupe, koja se sastoji od SEQ ID NO: 25, 153, 9, 185, 41, 57, 73, 89, 105, 121, 137, 169, 201 i 217; i laki lanac CDR3 domena koji je odabran iz grupe, koja se sastoji od SEQ ID NO: 33, 161, 17, 193, 49, 65, 81, 97, 113, 129, 145, 177, 209 i 225.
6. Antitelo ili antigen vezujući fragment, kao u patentnom zahtevu 5, koji dalje sadrže: teški lanac CDR1 domena koji je odabran iz grupe, koja se sastoji od SEQ ID NO: 21, 149, 5, 181, 37, 53, 69, 85, 101, 117, 133, 165, 197 i 213; teški lanac CDR2 domena koji je odabran iz grupe, koja se sastoji od SEQ ID NO: 23, 151, 7, 183, 39, 55, 71, 87, 103, 119, 135, 167, 199 i 215; laki lanac CDR1 domena koji je odabran iz grupe, koja se sastoji od SEQ ID NO: 29, 157, 13, 189, 45, 61, 77, 93, 109, 125, 141, 173, 205 i 221; i laki lanac CDR2 domena koji je odabran iz grupe, koja se sastoji od SEQ ID NO: 31, 159, 15, 191, 47, 63, 79, 95, 111, 127, 143, 175, 207 i 223.
7. Antitelo ili antigen vezujući fragment, kao u patentnom zahtevu 5 ili 6, gde CDR teškog lanca i CDR lakog lanca sadrže: SEQ ID NO: 21, 23, 25 i SEQ ID NO: 29, 31, 33; SEQ ID NO: 149, 151, 153 i SEQ ID NO: 157, 159, 161; SEQ ID NO: 5, 7, 9 i SEQ ID NO: 13, 15, 17; i SEQ ID NO: 181, 183, 185 i SEQ ID NO: 189, 191, odnosno 193.
8. Antitelo ili antigen vezujući fragment, kao u patentnom zahtevu 1 ili 2, koje sadrži varijabilni region teškog lanca (HCVR), odabran iz grupe, koja se sastoji od SEQ ID NO: 19, 147, 3, 179, 227, 231, 35, 51, 67, 83, 99, 115, 131, 239, 241, 163, 235, 195 i 211; i promenljivi region lakog lanca (LCVR), odabran iz grupe, koja se sastoji od SEQ ID NO: 27, 155, 11, 187, 229, 233, 43, 59, 75, 91, 107, 123, 139, 171, 237, 203 i 219.
9. Antitelo ili antigen vezujući fragment, kao u patentnom zahtevu 8, koje sadrži HCVR/LCVR parove, odabrane iz grupe, koja se sastoji od SEQ ID NO: 19/27; 147/155; 3/11; 179/187; 227/229; 231/233; 35/43; 51/59; 67/75; 83/91; 99/107; 115/123; 131/139; 239/155; 241/155; 163/171; 235/237; 195/203 i 211/219.
10. Izolovani molekul nukleinske kiseline koji kodira antitelo ili antigen vezujući fragment, kao u bilo kom od prethodnih patentnih zahteva.
11. Vektor, koji obuhvata nukleotidnu sekvencu, kao u patentnom zahtevu 10.
12. Sistem domaćin-vektor za proizvodnju antitela ili antigen vezujućeg fragmenta antitela koje specifično vezuje humani IL-6 receptor, koji obuhvata vektor, kao u patentnom zahtevu 11 u pogodnoj ćeliji domaćina.
13. Sistem domaćin-vektor, kao u patentnom zahtevu 12, u kome je ćelija domaćina prokariotska ili eukariotska ćelija odabrana od E. coli ili CHO ćelije.
14. Postupak proizvodnje anti-IL-6R antitela ili njegovog antigen-vezujućeg fragmenta, koji obuhvata uzgajanje ćelija sistema domaćin-vektor, kao u patentnom zahtevu 12 ili 13, u uslovima koji omogućavaju proizvodnju antitela ili njegovog fragmenta i vađenje tako proizvedenog antitela ili njegovog fragmenta.
15. Upotreba antitela ili antigen-vezujućeg fragmenta antitela, kao u bilo kom od patentnih zahteva 1 do 9, u proizvodnji leka za upotrebu za umanjivanje ili inhibiranje bolesti ili poremećaja kod ljudi, posredovanih IL-6.
16. Antitelo ili antigen-vezujući fragment antitela, kao u bilo kom od patentnih zahteva 1 do 9, za upotrebu u umanjivanju ili inhibiciji bolesti ili poremećaja kod ljudi, koji su posredovani IL-6.
17. Farmaceutska smeša koja sadrži antitelo ili antigen-vezujući fragment antitela, kao u bilo kom od patentnih zahteva 1 do 9 i, farmaceutski prihvatljiv nosač ili podlogu.
18. Postupak umanjivanja ili inhibisanja bolesti ili poremećaja kod ljudi, koji su posredovani IL-6, postupak obuhvata primenjivanje pacijentu čoveku, efektivne količine antitela ili antigen-vezujućeg fragmenta antitela, kao u bilo kom od patentnih zahteva 1 do 9.
19. Postupak, kao u patentnom zahtevu 18, u kome je bolest ili poremećaj posredovan IL-6 artritis, kao hronični reumatoidni artritis;
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81066406P | 2006-06-02 | 2006-06-02 | |
| US84323206P | 2006-09-08 | 2006-09-08 | |
| PCT/US2007/013062 WO2007143168A2 (en) | 2006-06-02 | 2007-06-01 | High affinity antibodies to human il-6 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME00519B true ME00519B (me) | 2011-10-10 |
Family
ID=38792460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-853A ME00519B (me) | 2006-06-02 | 2007-06-01 | Antitijela visokog afiniteta prema humanom il-6 receptoru |
Country Status (33)
| Country | Link |
|---|---|
| US (10) | US7582298B2 (me) |
| EP (2) | EP2374818B1 (me) |
| JP (3) | JP5307708B2 (me) |
| KR (1) | KR101464502B1 (me) |
| CN (2) | CN101454345B (me) |
| AT (1) | ATE537190T1 (me) |
| AU (1) | AU2007254831B2 (me) |
| BR (1) | BRPI0712224B8 (me) |
| CA (1) | CA2652976C (me) |
| CR (1) | CR10462A (me) |
| CY (3) | CY1112456T1 (me) |
| DK (2) | DK2041177T3 (me) |
| ES (2) | ES2398076T3 (me) |
| GT (1) | GT200800272A (me) |
| HR (2) | HRP20120175T1 (me) |
| HU (1) | HUS1700050I1 (me) |
| IL (1) | IL195393A (me) |
| LT (1) | LTC2041177I2 (me) |
| LU (1) | LUC00050I2 (me) |
| ME (1) | ME00519B (me) |
| MX (1) | MX2008014804A (me) |
| MY (2) | MY159787A (me) |
| NL (1) | NL300911I2 (me) |
| NO (2) | NO340778B1 (me) |
| NZ (2) | NZ587107A (me) |
| PL (2) | PL2041177T3 (me) |
| PT (2) | PT2041177E (me) |
| RS (2) | RS52643B (me) |
| RU (1) | RU2433138C2 (me) |
| SI (2) | SI2041177T1 (me) |
| SV (1) | SV2008003113A (me) |
| TN (1) | TNSN08502A1 (me) |
| WO (1) | WO2007143168A2 (me) |
Families Citing this family (381)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| DK1523496T3 (da) | 2002-07-18 | 2011-10-17 | Merus B V | Rekombinant fremstilling af blanding af antistoffer |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| EP2395016A3 (en) | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| BRPI0617664B8 (pt) | 2005-10-21 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio |
| WO2007114319A1 (ja) * | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 抗体の血中動態を制御する方法 |
| JP5754875B2 (ja) | 2006-04-07 | 2015-07-29 | 国立大学法人大阪大学 | 筋再生促進剤 |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| AU2007254831B2 (en) | 2006-06-02 | 2012-03-22 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CA2670583A1 (en) * | 2006-11-30 | 2008-06-05 | Medimmune, Llc | Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| KR101508019B1 (ko) | 2007-01-23 | 2015-04-06 | 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 | 만성 거부반응 억제제 |
| TWI501976B (zh) * | 2007-05-21 | 2015-10-01 | Alder Biopharmaceuticals Inc | 抗ＴＮＦ－α之抗體及其用途 |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| CA2688146C (en) | 2007-05-21 | 2018-03-06 | Alder Biopharmaceuticals, Inc. | Antibodies to il-6 and use thereof |
| SI2187964T1 (sl) | 2007-08-10 | 2015-01-30 | Regeneron Pharmaceuticals, Inc. | Visokoafinitetna humana protitelesa proti humanemu živčnemu rastnemu faktorju |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| PE20140132A1 (es) | 2007-09-26 | 2014-02-14 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-receptor de il-6 |
| CN101874041B (zh) | 2007-09-26 | 2013-06-19 | 中外制药株式会社 | 抗体恒定区修饰体 |
| EP2708559B1 (en) | 2008-04-11 | 2018-03-28 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| US8034344B2 (en) | 2008-05-13 | 2011-10-11 | Novimmune S.A. | Anti-IL-6/IL-6R antibodies and methods of use thereof |
| KR20110020860A (ko) * | 2008-05-23 | 2011-03-03 | 알리바 바이오파마수티컬스, 아이엔씨. | 유전자 삽입동물에서 단일 ｖｌ 도메인 항체를 생산하는 방법 |
| CN104906581A (zh) | 2008-06-05 | 2015-09-16 | 国立研究开发法人国立癌症研究中心 | 神经浸润抑制剂 |
| WO2009157771A2 (en) | 2008-06-27 | 2009-12-30 | Merus B.V. | Antibody producing non-human mammals |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| AU2012200724B8 (en) * | 2008-09-26 | 2014-09-11 | Chugai Seiyaku Kabushiki Kaisha | Improved antibody molecules |
| CN102245207B (zh) | 2008-11-13 | 2015-11-25 | 费塔制药股份有限公司 | 人源化抗il-6抗体 |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| ES2618181T3 (es) * | 2009-02-24 | 2017-06-21 | Esbatech, An Alcon Biomedical Research Unit Llc | Métodos para identificar inmunoaglutinantes de antígenos de superficie celular |
| JP5764071B2 (ja) * | 2009-02-24 | 2015-08-12 | エスバテック − ア ノバルティスカンパニー エルエルシー | 細胞表面抗原のイムノバインダーを同定するための方法 |
| TWI440470B (zh) * | 2009-03-19 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | 含改良抗體分子之醫藥配方 |
| EP3674317B1 (en) | 2009-03-19 | 2024-12-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| KR101470690B1 (ko) | 2009-04-10 | 2014-12-10 | 아블린쓰 엔.브이. | Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드 |
| US10618964B2 (en) * | 2009-04-10 | 2020-04-14 | Ablynx N.V. | Nanobody against IL-6R |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| EP2798950B2 (en) | 2009-07-08 | 2023-03-22 | Kymab Limited | Animal models and therapeutic molecules |
| WO2011066371A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antibodies to il-6 and use thereof |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| DK2493922T3 (en) | 2009-10-26 | 2017-04-24 | Hoffmann La Roche | Process for preparing a glycosylated immunoglobulin |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| CN110079550A (zh) | 2009-12-10 | 2019-08-02 | 瑞泽恩制药公司 | 生产重链抗体的小鼠 |
| JO3274B1 (ar) | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
| JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| JP5955781B2 (ja) | 2010-02-08 | 2016-07-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 共通の軽鎖のマウス |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| JP6033218B2 (ja) * | 2010-05-21 | 2016-11-30 | ペプティメド， インコーポレイテッド | がんを治療するための試薬および方法 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| JP6051049B2 (ja) | 2010-05-28 | 2016-12-21 | 中外製薬株式会社 | 抗腫瘍ｔ細胞応答増強剤 |
| CN103221063B (zh) | 2010-06-16 | 2016-08-24 | 特瑞利斯生物科学有限责任公司 | 针对人类巨细胞病毒(cmv)gb蛋白质的高亲和力人类抗体 |
| CN103154255B (zh) | 2010-08-02 | 2016-04-06 | 瑞泽恩制药公司 | 制造包含vl结构域的结合蛋白的小鼠 |
| US9533039B2 (en) | 2010-09-27 | 2017-01-03 | Regeneron Pharmaceuticals, Inc. | Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies |
| AR083044A1 (es) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
| JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| DK2643018T3 (da) | 2010-11-23 | 2021-01-18 | Vitaeris Inc | Anti-il-6-antistoffer til behandling af oral mucositis |
| TWI654204B (zh) | 2010-11-30 | 2019-03-21 | 中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| US20120189621A1 (en) | 2011-01-21 | 2012-07-26 | Yann Dean | Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists |
| PH12013501576A1 (en) | 2011-01-28 | 2013-09-30 | Sanofi Biotechnology | Pharmaceutical compositions comprising human antibodies to pcsk9 |
| RU2722373C2 (ru) | 2011-02-25 | 2020-05-29 | Редженерон Фармасьютикалс, Инк. | Мыши adam6 |
| JP6097702B2 (ja) * | 2011-03-03 | 2017-03-15 | アペクシジェン， インコーポレイテッド | 抗ｉｌ−６受容体抗体およびその使用方法 |
| RU2628310C2 (ru) | 2011-04-01 | 2017-08-15 | Чугаи Сейяку Кабусики Кайся | Способ получения рекомбинантного полипептида |
| DK2527842T3 (da) | 2011-05-12 | 2013-09-08 | Regeneron Pharma | Neuropeptidfrisætningsanalyse til natriumkanaler |
| JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| SI2739740T1 (sl) | 2011-08-05 | 2019-12-31 | Regeneron Pharmaceuticals, Inc. | Humanizirane univerzalne lahkoverižne miši |
| BR112014006390A2 (pt) | 2011-09-19 | 2017-03-28 | Kymab Ltd | anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano |
| AU2012311443B2 (en) | 2011-09-23 | 2016-12-01 | Ablynx Nv | Prolonged inhibition of interleukin-6 mediated signaling |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| BR112014007382A2 (pt) | 2011-09-30 | 2017-04-04 | Regeneron Pharma | anticorpos anti-erbb3 e seus usos |
| TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| SG10201914052TA (en) * | 2011-10-11 | 2020-03-30 | Sanofi Biotechnology | Compositions for the treatment of rheumatoid arthritis and methods of using same |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| HUE034321T2 (en) | 2011-10-17 | 2018-02-28 | Regeneron Pharma | Restricted immunoglobulin heavy chain mice |
| WO2013059548A1 (en) | 2011-10-19 | 2013-04-25 | Sanofi | Compositions and methods for treating cancer using jak2 inhibitor |
| CN103059137A (zh) * | 2011-10-21 | 2013-04-24 | 神州细胞工程有限公司 | 抗hIL6R高亲和力抗体的制备及应用 |
| WO2013059426A1 (en) * | 2011-10-21 | 2013-04-25 | The Regents Of The University Of California | Human endogenous retrovirus peptides, antibodies to the peptides, and methods of use thereof |
| PL2663575T3 (pl) | 2011-10-28 | 2015-03-31 | Regeneron Pharma | Humanizowane IL-6 i receptor IL-6 |
| JO3370B1 (ar) | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
| HUE038570T2 (hu) | 2011-11-14 | 2018-10-29 | Regeneron Pharma | Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával |
| PL2782598T3 (pl) | 2011-11-23 | 2021-03-08 | In3Bio Ltd. | Rekombinowane białka i ich zastosowania terapeutyczne |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| HRP20190897T1 (hr) | 2011-12-20 | 2019-09-20 | Regeneron Pharmaceuticals, Inc. | Laki lanac humaniziranih miševa |
| US9371383B2 (en) | 2012-01-31 | 2016-06-21 | Regeneron Pharmaceuticals, Inc. | Anti-ASIC1 antibodies and uses thereof |
| RS62454B1 (sr) * | 2012-01-31 | 2021-11-30 | Regeneron Pharma | Anti-asic1 antitela i njihove upotrebe |
| TWI613215B (zh) | 2012-02-22 | 2018-02-01 | 再生元醫藥公司 | 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途 |
| UY34652A (es) | 2012-03-02 | 2013-09-02 | Regeneron Pharma | Anticuerpos humanos frente a toxinas de clostridium difficile |
| JP2015509380A (ja) | 2012-03-06 | 2015-03-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 共通の軽鎖のマウス |
| CA2865644A1 (en) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
| RS57414B1 (sr) | 2012-03-16 | 2018-09-28 | Regeneron Pharma | Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih |
| EP3539374A1 (en) | 2012-03-16 | 2019-09-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing ph-sensitive immunoglobulin sequences |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| HRP20191409T1 (hr) | 2012-04-20 | 2019-11-15 | Merus Nv | Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| KR102484480B1 (ko) | 2012-06-12 | 2023-01-04 | 리제너론 파마슈티칼스 인코포레이티드 | 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물 |
| TW201843172A (zh) | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| IL312711A (en) | 2012-08-21 | 2024-07-01 | Regeneron Pharma | Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL |
| JO3462B1 (ar) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
| RS57520B1 (sr) | 2012-09-07 | 2018-10-31 | Regeneron Pharma | Postupci za lečenje atopijskog dermatitisa primenom antagonista il-4r |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| EP2920211A1 (en) | 2012-11-13 | 2015-09-23 | Regeneron Pharmaceuticals, Inc. | Anti-prokineticin receptor (prokr) antibodies and uses thereof |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| HRP20181151T1 (hr) | 2013-02-20 | 2018-09-21 | Regeneron Pharmaceuticals, Inc. | Neljudske životinje s modificiranim sekvencama imunoglobulinskog teškog lanca |
| JP6529957B2 (ja) | 2013-03-13 | 2019-06-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 限られた免疫グロブリン軽鎖レパートリーを発現するマウス |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| CA2903696A1 (en) | 2013-03-13 | 2014-10-02 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| EA201591754A1 (ru) | 2013-03-14 | 2016-01-29 | Ридженерон Фармасьютикалз, Инк. | Человеческие антитела к na1.7 |
| SG11201506459PA (en) | 2013-03-14 | 2015-09-29 | Regeneron Pharma | Human antibodies to grem 1 |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| EP3009518B1 (en) | 2013-06-11 | 2020-08-12 | National Center of Neurology and Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy |
| WO2014205365A1 (en) | 2013-06-21 | 2014-12-24 | Sanofi | Methods for treating nasal polyposis by administering an il-4r antagonist |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| WO2015027154A2 (en) | 2013-08-23 | 2015-02-26 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| RU2694728C2 (ru) | 2013-09-18 | 2019-07-16 | Регенерон Фармасьютикалз, Инк. | Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения |
| GB201316644D0 (en) | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
| EP3051942B1 (en) | 2013-10-01 | 2020-09-02 | Kymab Limited | Animal models and therapeutic molecules |
| RU2701684C2 (ru) | 2013-10-31 | 2019-09-30 | Ридженерон Фармасьютикалз, Инк. | Анализ конкурентного связывания с лигандом для обнаружения нейтрализирующих антител |
| BR112016011401A2 (pt) | 2013-11-20 | 2017-09-26 | Regeneron Pharma | moduladores de aplnr e utilizações dos mesmos |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| WO2015095511A2 (en) * | 2013-12-20 | 2015-06-25 | The Scripps Research Institute | Functional antibodies that modulate cell death and related methods |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| WO2015116852A1 (en) | 2014-01-29 | 2015-08-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating rheumatoid arthritis by administering an il-6r antibody |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| NZ724229A (en) | 2014-03-11 | 2023-06-30 | Regeneron Pharma | Anti-egfrviii antibodies and uses thereof |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| SG11201607015VA (en) | 2014-03-21 | 2016-09-29 | Regeneron Pharma | V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS |
| CA3124228C (en) | 2014-03-21 | 2024-05-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| SG11201701711VA (en) | 2014-09-16 | 2017-04-27 | Regeneron Pharma | Anti-glucagon antibodies and uses thereof |
| CA2961517C (en) | 2014-09-23 | 2023-05-02 | Regeneron Pharmaceuticals, Inc. | Anti-il-25 antibodies and uses thereof |
| CA2963712A1 (en) | 2014-10-21 | 2016-04-28 | Ablynx Nv | Treatment of il-6r related diseases |
| RU2734490C2 (ru) | 2014-11-14 | 2020-10-19 | Санофи Байотекнолоджи | Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r |
| HUE071048T2 (hu) | 2014-11-17 | 2025-07-28 | Regeneron Pharma | Daganatkezelési módszerek a CD3XCD20 bispecifikus antitest használatával |
| US20160152717A1 (en) * | 2014-12-02 | 2016-06-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating dry eye disease by administering an il-6r antagonist |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| ES2967627T3 (es) | 2015-02-27 | 2024-05-03 | Chugai Pharmaceutical Co Ltd | Composición para tratar enfermedades relacionadas con IL-6 |
| EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| CN107771081A (zh) | 2015-04-15 | 2018-03-06 | 瑞泽恩制药公司 | 用gdf8抑制剂增加力量和功能的方法 |
| JP2016208934A (ja) * | 2015-05-12 | 2016-12-15 | 学校法人日本大学 | 抗イヌインターロイキン−６受容体モノクローナル抗体又は抗体フラグメント及びその利用 |
| ES2888801T3 (es) | 2015-05-19 | 2022-01-07 | Nat Center Neurology & Psychiatry | Método para determinar la aplicación de una terapia nueva en pacientes con esclerosis múltiple (EM) |
| WO2016195088A1 (ja) | 2015-06-04 | 2016-12-08 | 国立研究開発法人 国立精神・神経医療研究センター | Ｉｌ－６阻害剤を有効成分とする精神疾患治療剤 |
| MY197218A (en) | 2015-07-06 | 2023-06-02 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| TWI797060B (zh) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| CA2995645A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| EP3184547A1 (en) * | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| WO2017112775A1 (en) | 2015-12-22 | 2017-06-29 | Regeneron Pharmaceuticals, Inc. | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer |
| SG11201803989WA (en) | 2015-12-28 | 2018-06-28 | Chugai Pharmaceutical Co Ltd | Method for promoting efficiency of purification of fc region-containing polypeptide |
| WO2017123804A1 (en) | 2016-01-13 | 2017-07-20 | Regeneron Pharmaceuticals, Inc. | Rodents having an engineered heavy chain diversity region |
| SG11201806427WA (en) | 2016-02-16 | 2018-08-30 | Regeneron Pharma | Non-human animals having a mutant kynureninase gene |
| EP3216461A1 (en) | 2016-03-07 | 2017-09-13 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
| IL308539A (en) | 2016-03-07 | 2024-01-01 | Sanofi Biotechnology | Preparations and methods for the treatment of rheumatoid arthritis |
| CN109789194B (zh) | 2016-04-08 | 2022-08-02 | 瑞泽恩制药公司 | 用angptl8抑制剂和angptl3抑制剂治疗高脂血症的方法 |
| SG11201807885PA (en) | 2016-04-20 | 2018-10-30 | Regeneron Pharma | Compositions and methods for making antibodies based on use of expression-enhancing loci |
| TW201803981A (zh) * | 2016-04-20 | 2018-02-01 | 再生元醫藥公司 | 用於以使用增強表現基因座爲基礎製造抗體之組成物及方法 |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| TWI786044B (zh) | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 |
| ES2977547T3 (es) | 2016-05-20 | 2024-08-26 | Regeneron Pharma | Métodos para romper la tolerancia inmunológica utilizando múltiples ARN guía |
| WO2017201731A1 (en) | 2016-05-27 | 2017-11-30 | Beijing Vdjbio Co., Ltd. | Antibodies, composition and kits comprising same, and methods of use thereof |
| WO2017214089A1 (en) | 2016-06-06 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies with human lambda light chains |
| IL263273B2 (en) | 2016-06-10 | 2025-10-01 | Regeneron Pharma | Antibodies against GITR and their uses |
| KR102667023B1 (ko) | 2016-06-14 | 2024-05-21 | 리제너론 파아마슈티컬스, 인크. | 항-c5 항체 및 이의 용도 |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| RU2656160C2 (ru) * | 2016-08-17 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| MA46098B1 (fr) | 2016-09-01 | 2024-11-29 | Regeneron Pharmaceuticals, Inc. | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
| BR112019005670A2 (pt) | 2016-09-23 | 2019-06-04 | Regeneron Pharmaceuticals, Inc. | anticorpos anti-muc16 (mucina 16) |
| EA201990781A9 (ru) | 2016-09-23 | 2019-11-27 | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| EP4567119A3 (en) | 2016-11-04 | 2025-09-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain locus |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| KR20190078650A (ko) | 2016-11-17 | 2019-07-04 | 리제너론 파아마슈티컬스, 인크. | 항-angptl8 항체를 사용하는 비만의 치료 방법 |
| EP3548514A1 (en) | 2016-11-29 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
| EP3548082B1 (en) | 2016-11-29 | 2024-05-15 | Regeneron Pharmaceuticals, Inc. | A pharmaceutical composition for averting opioid addiction |
| US10736976B2 (en) | 2016-12-01 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| US11352417B2 (en) | 2016-12-22 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| TW202311284A (zh) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| IL268667B2 (en) | 2017-02-10 | 2024-12-01 | Regeneron Pharma | Radiolabeled antibodies against LAG3 for immuno-PET imaging |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| EP3630814A1 (en) | 2017-06-01 | 2020-04-08 | Regeneron Pharmaceuticals, Inc. | Human antibodies to bet v 1 and methods of use thereof |
| BR112019025888A2 (pt) | 2017-06-07 | 2020-06-30 | Regeneron Pharmaceuticals, Inc. | polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| AU2018287519B2 (en) | 2017-06-22 | 2021-07-22 | Novartis Ag | IL-1beta binding antibodies for use in treating cancer |
| KR102877389B1 (ko) | 2017-06-28 | 2025-10-28 | 리제너론 파아마슈티컬스, 인크. | 항-인간 유두종 바이러스 (hpv) 항원-결합 단백질 및 그의 사용 방법 |
| AU2018298039B2 (en) | 2017-07-06 | 2023-02-02 | Regeneron Pharmaceuticals, Inc. | Cell culture process for making a glycoprotein |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| RU2020111737A (ru) | 2017-09-13 | 2021-10-13 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Антитело против il-6r и его антигенсвязывающий фрагмент и медицинское применение |
| BR112020004977A2 (pt) | 2017-09-29 | 2020-10-06 | Regeneron Pharmaceuticals, Inc. | moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos |
| WO2019078344A1 (ja) | 2017-10-20 | 2019-04-25 | 学校法人兵庫医科大学 | 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
| KR20250044796A (ko) | 2017-10-30 | 2025-04-01 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| CN121181700A (zh) | 2017-11-30 | 2025-12-23 | 瑞泽恩制药公司 | 抗trkb单克隆抗体及其使用方法 |
| CA3084049A1 (en) | 2017-12-05 | 2019-06-13 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof |
| SG11202004662RA (en) | 2017-12-13 | 2020-06-29 | Regeneron Pharma | Anti-c5 antibody combinations and uses thereof |
| WO2019126194A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| MA51289A (fr) | 2017-12-18 | 2021-03-24 | Regeneron Pharma | Molécules de liaison à l'antigène bispécifiques se liant au récepteur de la leptine et/ou à gp130, et leurs procédés d'utilisation |
| JP7321159B2 (ja) | 2017-12-22 | 2023-08-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 薬剤生成物不純物を特性決定するためのシステム及び方法 |
| BR112020014849A2 (pt) | 2018-01-26 | 2020-12-08 | Regeneron Pharmaceuticals, Inc. | Anticorpo recombinante isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma de infecção por influenza |
| AU2019215363A1 (en) | 2018-01-31 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| AU2019218892B2 (en) | 2018-02-07 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
| SG11202006310PA (en) | 2018-02-28 | 2020-07-29 | Regeneron Pharma | Systems and methods for identifying viral contaminants |
| MA52417A (fr) | 2018-03-01 | 2021-01-06 | Regeneron Pharma | Procédés de modification de composition corporelle |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| PL3768709T3 (pl) | 2018-03-19 | 2024-05-20 | Regeneron Pharmaceuticals, Inc. | Analizy mikroczipowej elektroforezy kapilarnej i stosowane w nich odczynniki |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| CN112088166A (zh) | 2018-03-26 | 2020-12-15 | 瑞泽恩制药公司 | 抗PfRH5抗体和其抗原结合片段 |
| JP7328990B2 (ja) | 2018-04-30 | 2023-08-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用 |
| KR20210008008A (ko) | 2018-05-09 | 2021-01-20 | 리제너론 파마슈티칼스 인코포레이티드 | 항-msr1 항체 및 이의 사용 방법 |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| SG11202011232VA (en) | 2018-05-17 | 2020-12-30 | Regeneron Pharma | Anti-cd63 antibodies, conjugates, and uses thereof |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| CA3104470A1 (en) | 2018-06-19 | 2019-12-26 | Regeneron Pharmaceuticals, Inc. | Anti-factor xii/xiia antibodies and uses thereof |
| KR20250156829A (ko) | 2018-06-21 | 2025-11-03 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-psma x 항-cd28 항체 및 이의 용도 |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| KR102901020B1 (ko) | 2018-07-19 | 2025-12-19 | 리제너론 파아마슈티컬스, 인크. | Bcma 특이성을 갖는 키메라 항원 수용체 및 이의 용도 |
| JP7460598B2 (ja) | 2018-08-10 | 2024-04-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 膝および／または股関節痛の安全で効果的な処置用の医薬組成物 |
| MX2021002165A (es) | 2018-08-23 | 2021-07-16 | Regeneron Pharma | Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos. |
| BR112020024296A2 (pt) | 2018-08-27 | 2021-03-09 | Regeneron Pharmaceuticals, Inc. | Métodos para produção de um intermediário de purificação de proteína concentrado, para monitoramento e controle dos atributos de qualidade críticos em um intermediário de purificação de proteína e para monitorar e controlar os níveis de excipientes no fluido de cultura de células colhido e/ou intermediário de purificação de proteína, e, intermediário de purificação de proteína |
| MX2021002422A (es) | 2018-08-29 | 2021-07-15 | Regeneron Pharma | Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide. |
| TWI866924B (zh) | 2018-08-30 | 2024-12-21 | 美商再生元醫藥公司 | 用於將蛋白質複合物定特徵之方法 |
| MX2021004284A (es) | 2018-10-23 | 2021-05-31 | Regeneron Pharma | Anticuerpos anti-npr1 y usos de los mismos. |
| EP3876989A4 (en) * | 2018-11-09 | 2022-12-07 | University of Massachusetts | Anti-cfae antibodies and methods of use |
| MX2021005863A (es) | 2018-11-21 | 2021-07-16 | Regeneron Pharma | Anticuerpos antiestafilococo y usos de estos. |
| US11453721B2 (en) | 2018-12-19 | 2022-09-27 | Regeneran Pharmaceuticals, Inc. | Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof |
| CA3124168A1 (en) | 2018-12-19 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof |
| US20220025036A1 (en) | 2018-12-21 | 2022-01-27 | Novartis Ag | Use of il-1beta binding antibodies |
| AU2020205951A1 (en) * | 2019-01-07 | 2021-07-22 | Hunan Siweikang Therapeutics Co. Ltd | Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy |
| SG11202104103XA (en) | 2019-01-16 | 2021-05-28 | Regeneron Pharma | Methods for characterizing disulfide bonds |
| TW202521583A (zh) | 2019-01-31 | 2025-06-01 | 法商賽諾菲生物技術公司 | 用於治療幼年原發性關節炎之組成物及方法 |
| KR20210126641A (ko) | 2019-02-12 | 2021-10-20 | 리제너론 파아마슈티컬스, 인크. | 보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법 |
| EP3927435A1 (en) | 2019-02-21 | 2021-12-29 | Regeneron Pharmaceuticals, Inc. | Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met |
| WO2020178193A1 (en) | 2019-03-01 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of treatment of sarcoidosis |
| AU2020240132A1 (en) | 2019-03-21 | 2021-09-16 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
| EA202192566A1 (ru) | 2019-03-22 | 2021-12-27 | Ридженерон Фармасьютикалз, Инк. | МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28 |
| US20220185900A1 (en) | 2019-04-10 | 2022-06-16 | Regeneron Pharmaceuticals, Inc. | Human antibodies that bind ret and methods of use thereof |
| CA3137909A1 (en) | 2019-04-24 | 2020-10-29 | Sanofi Biotechnology | Methods of diagnosis and treatment of rheumatoid arthritis |
| BR112021021195A2 (pt) | 2019-05-01 | 2022-03-03 | Regeneron Pharma | Métodos para tratamento ou prevenção da asma pela administração de um antagonista de il-33 |
| CN113785203A (zh) | 2019-05-13 | 2021-12-10 | 里珍纳龙药品有限公司 | 改进的竞争性配体结合测定 |
| US12297279B2 (en) | 2019-06-04 | 2025-05-13 | Sanofi Biotechnology | Compositions and methods for treating pain in subjects with rheumatoid arthritis |
| AU2020289554A1 (en) | 2019-06-05 | 2021-11-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof |
| CN113966343A (zh) | 2019-06-11 | 2022-01-21 | 瑞泽恩制药公司 | 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法 |
| WO2020252478A2 (en) * | 2019-06-14 | 2020-12-17 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-1 and methods of use thereof |
| CA3141628A1 (en) * | 2019-06-14 | 2020-12-17 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-1 and methods of use thereof |
| WO2020257586A2 (en) | 2019-06-20 | 2020-12-24 | Baxalta Incorporated | Method of treatment with viral-based gene therapy |
| AU2020315369A1 (en) | 2019-07-16 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| US20220281994A1 (en) | 2019-07-24 | 2022-09-08 | Regeneron Pharmaceuticals, Inc. | Chimeric Antigen Receptors with MAGE-A4 Specificity and Uses Thereof |
| MX2022002886A (es) | 2019-09-16 | 2022-04-06 | Regeneron Pharma | Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet. |
| IL291020B2 (en) | 2019-09-24 | 2025-04-01 | Regeneron Pharma | Systems and methods for use in chromatography and regeneration |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| CN114761428A (zh) | 2019-10-28 | 2022-07-15 | 瑞泽恩制药公司 | 抗血凝素抗体及其使用方法 |
| EP4065086B1 (en) | 2019-11-25 | 2026-01-28 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| KR20220110510A (ko) | 2019-12-06 | 2022-08-08 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-BCMA x 항-CD3 항체를 이용한 다발성 골수종의 치료 방법 |
| KR20220110553A (ko) | 2019-12-06 | 2022-08-08 | 사노피 바이오테크놀로지 | Il-33 길항제를 투여하여 copd를 치료하는 방법 |
| BR112022011388A2 (pt) | 2019-12-23 | 2022-08-30 | Sanofi Biotechnology | Métodos para tratar ou prevenir asma alérgica administrando um antagonista de il-33 e/ou um antagonista de il-4r |
| JP7342279B2 (ja) | 2020-01-21 | 2023-09-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グリコシル化タンパク質の電気泳動のための脱グリコシル化方法 |
| EP4093767A1 (en) | 2020-01-22 | 2022-11-30 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor |
| IL294529A (en) | 2020-02-10 | 2022-09-01 | Regeneron Pharma | Anti-tmprss2 antibodies and antigen-binding fragments |
| US11945872B2 (en) | 2020-02-11 | 2024-04-02 | Regeneron Pharmaceuticals, Inc. | Anti-ACVR1 antibodies and uses thereof |
| MX2022010599A (es) | 2020-02-28 | 2022-09-09 | Regeneron Pharma | Moleculas biespecificas de union al antigeno que se unen a her2, y metodos de uso de los mismos. |
| JP7566923B2 (ja) | 2020-03-06 | 2024-10-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｇｉｔｒ抗体およびその使用 |
| PE20221893A1 (es) | 2020-04-02 | 2022-12-13 | Regeneron Pharma | Anticuerpos contra glicoproteina de espicula anti-sars-cov-2 y fragmentos de union al antigeno |
| WO2021226249A1 (en) * | 2020-05-06 | 2021-11-11 | Sorrento Therapeutics, Inc. | Neutralizing antibodies that bind the sars-cov-2 s protein |
| JP7702428B2 (ja) | 2020-05-12 | 2025-07-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｇｌｐ１ｒアンタゴニスト抗体およびその使用方法 |
| JP7525762B2 (ja) * | 2020-05-18 | 2024-07-31 | ビオシオン インコーポレイテッド | Ｉｌ６ｒに結合する抗体及びその使用 |
| WO2021242815A1 (en) | 2020-05-26 | 2021-12-02 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| JP2023527059A (ja) | 2020-05-26 | 2023-06-26 | サノフィ・バイオテクノロジー | 関節リウマチを治療するためのインターロイキン６受容体に対する抗体を含む組成物およびその使用方法 |
| MX2022015030A (es) | 2020-05-29 | 2023-01-04 | Sanofi Biotechnology | Composiciones y metodos para el tratamiento del dolor no inflamatorio en sujetos con artritis reumatoide. |
| CN116096402A (zh) * | 2020-06-16 | 2023-05-09 | 高诚生物医药(杭州)有限公司 | 与抗人冠状病毒的中和抗体相关的方法和组合物 |
| US20230416343A1 (en) * | 2020-08-07 | 2023-12-28 | Sorrento Therapeutics, Inc. | Neutralizing Antibodies that Bind the SARS-COV-2 S Protein |
| AU2021327238A1 (en) | 2020-08-20 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists |
| WO2022046925A1 (en) | 2020-08-26 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| US12163122B2 (en) | 2020-08-31 | 2024-12-10 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| CA3187680A1 (en) | 2020-09-11 | 2022-03-17 | Yashu Liu | Identification and production of antigen-specific antibodies |
| US11905332B2 (en) | 2020-09-18 | 2024-02-20 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof |
| CA3194111A1 (en) | 2020-10-05 | 2022-04-14 | Christine XU | Methods for treating asthma in pediatric subjects by administering an il-4r antagonist |
| NZ797493A (en) | 2020-10-22 | 2024-05-31 | Regeneron Pharma | Anti-fgfr2 antibodies and methods of use thereof |
| IL303027A (en) | 2020-11-25 | 2023-07-01 | Regeneron Pharma | Sustained release formulations by creating a non-aqueous membrane emulsion |
| EP4262757A1 (en) | 2020-12-17 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| WO2022133239A1 (en) | 2020-12-18 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to npr1 agonists |
| JP7758739B2 (ja) | 2020-12-23 | 2025-10-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アンカー改変型抗体をコードする核酸およびその使用 |
| JP2024503408A (ja) | 2021-01-20 | 2024-01-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 細胞培養におけるタンパク質力価の改善方法 |
| EP4302098A1 (en) | 2021-03-03 | 2024-01-10 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
| WO2022187626A1 (en) | 2021-03-05 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments |
| IL305731A (en) | 2021-03-26 | 2023-11-01 | Regeneron Pharma | Methods and systems for developing mixing protocols |
| KR102871709B1 (ko) | 2021-04-20 | 2025-10-17 | 리제너론 파마슈티칼스 인코포레이티드 | 아르테민에 대한 인간 항체 및 이의 사용 방법 |
| JP2024516308A (ja) | 2021-05-04 | 2024-04-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｍａｇｅ－ａ４特異性を有するキメラ抗原受容体及びその使用 |
| US20220372168A1 (en) | 2021-05-04 | 2022-11-24 | Regeneron Pharmaceuticals, Inc. | Multispecific fgf21 receptor agonists and their uses |
| CN117730099A (zh) | 2021-05-11 | 2024-03-19 | 瑞泽恩制药公司 | 抗tmprss6抗体及其用途 |
| AU2022286340A1 (en) | 2021-06-01 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| CN117460748A (zh) * | 2021-06-01 | 2024-01-26 | 法国施维雅药厂 | 抗nkg2a抗体和组合物 |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| EP4367134A1 (en) | 2021-07-05 | 2024-05-15 | Regeneron Pharmaceuticals, Inc. | Utilization of antibodies to shape antibody responses to an antigen |
| AU2022311906A1 (en) | 2021-07-14 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| AU2022316939A1 (en) | 2021-07-26 | 2024-03-07 | Regeneron Pharmaceuticals, Inc. | Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist |
| TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法 |
| AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| KR20240090312A (ko) | 2021-10-07 | 2024-06-21 | 리제너론 파아마슈티컬스, 인크. | Ph 미터 보정 및 교정 |
| MX2024004107A (es) | 2021-10-07 | 2024-04-19 | Regeneron Pharma | Sistemas y metodos para modelar y controlar el ph. |
| CA3235380A1 (en) | 2021-10-20 | 2023-04-27 | Elizabeth Laws | Methods for treating prurigo nodularis by administering an il-4r antagonist |
| KR20240099304A (ko) | 2021-10-22 | 2024-06-28 | 리제너론 파아마슈티컬스, 인크. | 인자 xi a2 도메인 결합 항체 및 이의 사용 방법 |
| CN118176167A (zh) | 2021-10-26 | 2024-06-11 | 瑞泽恩制药公司 | 用于产生实验室用水和分配处于不同温度的实验室用水的系统和方法 |
| WO2023092052A1 (en) | 2021-11-19 | 2023-05-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for reducing centralized pain |
| KR20240112973A (ko) | 2021-12-06 | 2024-07-19 | 리제너론 파아마슈티컬스, 인크. | 길항제 항-npr1 항체 및 이의 사용 방법 |
| EP4493921A1 (en) | 2022-03-18 | 2025-01-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| WO2023196903A1 (en) | 2022-04-06 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof |
| EP4514849A1 (en) | 2022-04-27 | 2025-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for selecting patients for treatment with an ngf antagonist |
| AU2023271827A1 (en) | 2022-05-18 | 2024-12-05 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof |
| WO2024015816A1 (en) | 2022-07-12 | 2024-01-18 | Regeneron Pharmaceuticals, Inc. | Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof |
| WO2024047021A1 (en) | 2022-08-29 | 2024-03-07 | Sanofi | Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist |
| EP4615882A1 (en) | 2022-11-07 | 2025-09-17 | Regeneron Pharmaceuticals, Inc. | Factor xi catalytic domain-binding antibodies and methods of use thereof |
| WO2024107752A2 (en) | 2022-11-15 | 2024-05-23 | Onestone Therapeutics Llc | Compositions and methods for immunomodulatory bifunctional fusion molecules |
| KR20250124178A (ko) | 2022-12-16 | 2025-08-19 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피 칼럼의 무결성을 평가하기 위한 방법 및 시스템 |
| WO2024130165A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome |
| WO2024152014A1 (en) | 2023-01-13 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| US20240248097A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| WO2024158880A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| WO2024163708A1 (en) | 2023-02-01 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| IL322397A (en) | 2023-02-13 | 2025-09-01 | Regeneron Pharma | Treating muscle-related disorders with anti-human CACNG1 antibodies |
| US20240299601A1 (en) | 2023-02-17 | 2024-09-12 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| TW202446462A (zh) | 2023-02-22 | 2024-12-01 | 美商再生元醫藥公司 | 系統適用性參數及管柱老化 |
| KR20250160361A (ko) | 2023-03-22 | 2025-11-12 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 만성 폐쇄성 폐 질환(copd)을 치료하는 방법 |
| TW202508625A (zh) | 2023-05-01 | 2025-03-01 | 美商再生元醫藥公司 | 使用苯酚或苯甲醇之多劑量抗體藥物產品 |
| CN121039163A (zh) | 2023-05-02 | 2025-11-28 | 瑞泽恩制药公司 | 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途 |
| AU2024304472A1 (en) | 2023-06-16 | 2026-01-08 | Regeneron Pharmaceuticals, Inc. | Cd40 x cd40 bispecific antigen-binding molecules and uses thereof |
| WO2025014914A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Bispecific pd-l1x4-1bb antibodies and methods of use thereof |
| CN119285767B (zh) * | 2023-07-10 | 2025-11-18 | 东莞市朋志生物科技有限公司 | 抗白介素-6抗体、检测白介素-6的试剂和试剂盒 |
| WO2025014913A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Bispecific pd-l1xcd28 antibodies and methods of use thereof |
| AU2023454911A1 (en) | 2023-07-10 | 2026-01-22 | Regeneron Pharmaceuticals, Inc. | Anti-human cacng1 antibody-drug conjugates and uses thereof |
| AU2024291721A1 (en) | 2023-07-19 | 2026-01-22 | Regeneron Pharmaceuticals, Inc. | ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF |
| US20250086164A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20250095773A1 (en) | 2023-09-18 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| WO2025072597A2 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| US20250145662A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025149845A1 (en) | 2024-01-12 | 2025-07-17 | Sanofi Biotechnology | Treatment of subjects with polymyalgia rheumatica who have been receiving a steroid |
| WO2025149846A1 (en) | 2024-01-12 | 2025-07-17 | Sanofi Biotechnology | Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| US20250388685A1 (en) | 2024-04-15 | 2025-12-25 | Sanofi Biotechnology | Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| US20260000758A1 (en) | 2024-06-28 | 2026-01-01 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof |
| WO2026015729A1 (en) | 2024-07-11 | 2026-01-15 | Regeneron Pharmaceuticals, Inc. | Gprc5d x cd28 bispecific antibodies and methods of use thereof |
| CN119775414B (zh) * | 2025-03-12 | 2025-06-06 | 武汉伊莱瑞特生物科技股份有限公司 | 抗猴白介素-6单克隆抗体、酶联免疫检测试剂盒及其应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171840A (en) | 1988-01-22 | 1992-12-15 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
| US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5216128A (en) | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
| ATE144713T1 (de) * | 1989-07-20 | 1996-11-15 | Tadamitsu Kishimoto | Antikörper gegen menschlichen interleukin-6- rezeptor |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| AU668349B2 (en) | 1991-04-25 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
| JPH05227970A (ja) * | 1992-02-19 | 1993-09-07 | Chugai Pharmaceut Co Ltd | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 |
| FR2694767B1 (fr) * | 1992-08-13 | 1994-10-21 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
| WO1994009138A1 (en) | 1992-10-20 | 1994-04-28 | Cetus Oncology Corporation | Interleukin-6 receptor antagonists |
| US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| AU7967294A (en) * | 1993-10-06 | 1995-05-01 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
| PL186506B1 (pl) | 1994-10-07 | 2004-01-30 | Chugai Pharmaceutical Co Ltd | Sposób wytwarzania środka farmaceutycznego hamującego wzrost komórek błony maziowej i zastosowanie monoklonalnego przeciwciała |
| HU225392B1 (en) | 1994-10-21 | 2006-11-28 | Chugai Pharmaceutical Co Ltd | Use of an antibody againts interleukin-6-receptor for producing a pharmaceutical composition for treating anemia and cachexia caused by il-6 production |
| KR100252743B1 (ko) | 1994-12-29 | 2000-09-01 | 나가야마 오사무 | Il-6 안타고니스트를 함유하는 항종양제의 작용증강제 |
| DK0811384T3 (da) | 1995-02-13 | 2006-10-09 | Chugai Pharmaceutical Co Ltd | Muskelproteinnedbrydningsinhibitor indeholdende IL-6-receptor-antistof |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US5785965A (en) | 1996-05-15 | 1998-07-28 | The Board Of Trustees Of The Leland Stanford Junior Univ. | VEGF gene transfer into endothelial cells for vascular prosthesis |
| ATE326238T1 (de) | 1996-06-27 | 2006-06-15 | Chugai Pharmaceutical Co Ltd | Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann |
| PT1004315E (pt) | 1997-08-15 | 2008-07-09 | Chugai Pharmaceutical Co Ltd | Profilácticos e/ou medicamentos contendo anticorpos neutralizantes anti-receptor de il-6 para reduzir a excreção de proteínas urinárias no lúpus eritematoso sistémico |
| US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| US6723319B1 (en) | 1998-03-17 | 2004-04-20 | Chugai Seiyaku Kabushiki Kaisha | Method of treating inflammatory intestinal diseases containing as the ingredient IL-6 receptors antibodies |
| ES2276525T3 (es) | 1998-08-24 | 2007-06-16 | Chugai Seiyaku Kabushiki Kaisha | Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo. |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| AU2001277781A1 (en) | 2000-08-11 | 2002-02-25 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing preparations |
| AU2002210918B2 (en) | 2000-10-20 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Degraded agonist antibody |
| CA2426679C (en) | 2000-10-25 | 2012-11-20 | Chugai Seiyaku Kabushiki Kaisha | Preventive or therapeutic agent for psoriasis comprising il-6 antagonist as active ingredient |
| WO2002036165A1 (fr) | 2000-10-27 | 2002-05-10 | Chugai Seiyaku Kabushiki Kaisha | Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| CN101721362B (zh) | 2002-02-14 | 2018-07-03 | 中外制药株式会社 | 包含抗体的溶液制剂 |
| US20060078533A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| US20060078532A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20060078531A1 (en) | 2004-10-12 | 2006-04-13 | Osemwota Sota | Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20060275294A1 (en) | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
| KR20050058486A (ko) * | 2002-08-30 | 2005-06-16 | 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 인간형 항인간 인터루킨-6 항체 및 항체 단편 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| JP4960096B2 (ja) | 2003-09-22 | 2012-06-27 | ペントラコール ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−６の生物学的効果を減じる化合物の使用 |
| US8617550B2 (en) | 2003-12-19 | 2013-12-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of vasculitis with IL-6 antagonist |
| CA2555688C (en) | 2004-02-11 | 2011-11-08 | Warner-Lambert Company Llc | Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies |
| US20070036788A1 (en) | 2004-09-22 | 2007-02-15 | Ahmed Sheriff | Use of a compound for reducing the biological effectiveness of il-6 |
| WO2006046661A1 (ja) * | 2004-10-28 | 2006-05-04 | Osaka University | インターロイキン－６阻害剤 |
| CA2591587A1 (en) | 2004-12-16 | 2006-06-22 | Genentech, Inc. | Methods for treating autoimmune disorders |
| US7700738B2 (en) * | 2005-01-27 | 2010-04-20 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| AU2007254831B2 (en) * | 2006-06-02 | 2012-03-22 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| RU2319351C1 (ru) * | 2006-09-13 | 2008-03-20 | Олег Иванович Квасенков | Способ подготовки к хранению яблок свежих специального назначения |
| CA2667466A1 (en) | 2006-10-27 | 2008-05-02 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
| US20100267934A1 (en) | 2007-05-31 | 2010-10-21 | Genmab A/S | Stable igg4 antibodies |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| WO2009109584A1 (en) | 2008-03-07 | 2009-09-11 | Ferring International Center S. A. | ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX |
-
2007
- 2007-06-01 AU AU2007254831A patent/AU2007254831B2/en active Active
- 2007-06-01 JP JP2009513324A patent/JP5307708B2/ja active Active
- 2007-06-01 MY MYPI2012001581A patent/MY159787A/en unknown
- 2007-06-01 RS RS20130051A patent/RS52643B/sr unknown
- 2007-06-01 SI SI200730858T patent/SI2041177T1/sl unknown
- 2007-06-01 EP EP11171039A patent/EP2374818B1/en active Active
- 2007-06-01 DK DK07777380.2T patent/DK2041177T3/da active
- 2007-06-01 MX MX2008014804A patent/MX2008014804A/es active IP Right Grant
- 2007-06-01 CA CA2652976A patent/CA2652976C/en active Active
- 2007-06-01 PL PL07777380T patent/PL2041177T3/pl unknown
- 2007-06-01 PT PT07777380T patent/PT2041177E/pt unknown
- 2007-06-01 WO PCT/US2007/013062 patent/WO2007143168A2/en not_active Ceased
- 2007-06-01 ES ES11171039T patent/ES2398076T3/es active Active
- 2007-06-01 ES ES07777380T patent/ES2377579T3/es active Active
- 2007-06-01 PL PL11171039T patent/PL2374818T3/pl unknown
- 2007-06-01 PT PT111710398T patent/PT2374818E/pt unknown
- 2007-06-01 US US11/809,482 patent/US7582298B2/en active Active
- 2007-06-01 HR HR20120175T patent/HRP20120175T1/hr unknown
- 2007-06-01 RS RS20120074A patent/RS52176B/sr unknown
- 2007-06-01 CN CN200780019546XA patent/CN101454345B/zh active Active
- 2007-06-01 NZ NZ587107A patent/NZ587107A/en unknown
- 2007-06-01 BR BRPI0712224A patent/BRPI0712224B8/pt active IP Right Grant
- 2007-06-01 RU RU2008152443/10A patent/RU2433138C2/ru active
- 2007-06-01 ME MEP-2008-853A patent/ME00519B/me unknown
- 2007-06-01 SI SI200731155T patent/SI2374818T1/sl unknown
- 2007-06-01 AT AT07777380T patent/ATE537190T1/de active
- 2007-06-01 EP EP07777380A patent/EP2041177B1/en active Active
- 2007-06-01 MY MYPI20084757A patent/MY147468A/en unknown
- 2007-06-01 NZ NZ573557A patent/NZ573557A/en unknown
- 2007-06-01 CN CN2012100596311A patent/CN102585002A/zh active Pending
- 2007-06-01 DK DK11171039.8T patent/DK2374818T3/da active
-
2008
- 2008-11-19 IL IL195393A patent/IL195393A/en active IP Right Grant
- 2008-11-26 CR CR10462A patent/CR10462A/es unknown
- 2008-11-28 SV SV2008003113A patent/SV2008003113A/es unknown
- 2008-12-02 GT GT200800272A patent/GT200800272A/es unknown
- 2008-12-02 TN TNP2008000502A patent/TNSN08502A1/en unknown
- 2008-12-05 KR KR1020087029749A patent/KR101464502B1/ko active Active
- 2008-12-18 NO NO20085309A patent/NO340778B1/no active Protection Beyond IP Right Term
-
2009
- 2009-07-13 US US12/501,657 patent/US8043617B2/en active Active
-
2011
- 2011-09-12 US US13/230,081 patent/US8183014B2/en active Active
-
2012
- 2012-03-07 CY CY20121100231T patent/CY1112456T1/el unknown
- 2012-04-18 US US13/450,011 patent/US20130157313A1/en not_active Abandoned
-
2013
- 2013-02-21 CY CY20131100159T patent/CY1113708T1/el unknown
- 2013-03-15 HR HRP20130228TT patent/HRP20130228T1/hr unknown
- 2013-05-15 JP JP2013102655A patent/JP5805703B2/ja active Active
-
2014
- 2014-03-12 US US14/206,259 patent/US20140255995A1/en not_active Abandoned
-
2015
- 2015-09-01 JP JP2015171640A patent/JP6140777B2/ja active Active
-
2016
- 2016-04-22 US US15/136,152 patent/US9884916B2/en active Active
-
2017
- 2017-11-13 CY CY2017039C patent/CY2017039I1/el unknown
- 2017-11-14 NO NO2017060C patent/NO2017060I1/no unknown
- 2017-11-15 NL NL300911C patent/NL300911I2/nl unknown
- 2017-11-22 LU LU00050C patent/LUC00050I2/en unknown
- 2017-11-23 LT LTPA2017038C patent/LTC2041177I2/lt unknown
- 2017-12-01 HU HUS1700050C patent/HUS1700050I1/hu unknown
-
2018
- 2018-08-31 US US16/119,695 patent/US10584173B2/en active Active
-
2020
- 2020-01-28 US US16/774,945 patent/US11370843B2/en active Active
-
2022
- 2022-05-20 US US17/749,728 patent/US20230094591A1/en not_active Abandoned
-
2024
- 2024-11-01 US US18/935,325 patent/US20250206829A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00519B (me) | Antitijela visokog afiniteta prema humanom il-6 receptoru | |
| ES2881602T3 (es) | Conjugados de anticuerpo-fynómero | |
| JP2022191486A (ja) | ヒト抗ｉｌ－３３中和モノクローナル抗体 | |
| JP6883591B2 (ja) | 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び使用 | |
| CA2901462C (en) | Antibodies that bind il-23 | |
| CN102037016B (zh) | 针对粒细胞巨噬细胞集落刺激因子的抗体 | |
| RU2019113790A (ru) | Анти-lag-3 антитела и их композиции | |
| JP2016503412A5 (ja) | Ｉｌ−６アンタゴニストおよびその使用 | |
| US20200277366A1 (en) | MULTI-SPECIFIC ANTIBODY MOLECULES HAVING SPECIFICITY FOR TNF-ALPHA, IL-17A and IL-17F | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2011514150A5 (me) | ||
| RU2011120194A (ru) | Человеческие антитела с высокой аффинностью к рецепторам il-4 человека | |
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| CN108409860A (zh) | 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用 | |
| HRP20160638T1 (hr) | Antigen vezujući proteini sposobni vezati timusni stromalni limfopoetin | |
| JP2009539349A5 (me) | ||
| RU2011145428A (ru) | АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ | |
| EP3215529A1 (en) | Anti-tnf-/anti-il-23 bispecific antibodies | |
| RU2019123112A (ru) | Анти-il-5 антитела | |
| EP3154564B1 (en) | New polypeptide | |
| AU2018450414B2 (en) | Anti-IL-25 antibodies and use thereof | |
| CN117860786B (zh) | 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途 | |
| KR102048475B1 (ko) | IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도 | |
| RU2841957C1 (ru) | Сконструированные антитела против il-2 | |
| CN120349412B (zh) | 新型抗il-17a单域抗体、制备及其应用 |